Immunohistological analyses of tumor tissues with antibodies against the proliferation and blood vessel markers Ki67 and CD31, respectively, revealed no statistically significant effect of APG350 or TRAIL on tumor cell proliferation or neo-angiogenesis (Figs. 6e–g). Here, PECAM1 is linked to neoplasm.